3. Liver Transplantation

3.1 Induction Therapy

3.2 Maintenance Therapy

3.2.1 Calcineurin Inhibitors

3.2.2 Antimetabolite

3.2.3 mTOR Inhibitor

3.2.4 Co-Stimulation Blockade

3.2.5 Other

3.3 ABO-Incompatible Liver Transplantation

3.4 Management of Rejection

3.5 Hepatic Diseases

3.5.1 Acute Hepatic Necrosis

3.5.2 Biliary Atresia

3.5.3 Malignant Neoplasms

3.5.4 Metabolic Diseases

3.5.5 Cholestatic Liver Disease / Cirrhosis and Non-Cholestatic Cirrhosis

3.1 Induction Therapy


- Open-label, multicenter, RCT comparing rATG induction with delayed CNI initiation (day-10) (n=55) to upfront CNI commencement (SOC: standard of care) (n=55) in patients at standard risk of postoperative renal dysfunction following liver transplant. A significant difference in change in creatinine was observed between rATG and SOC groups at 9-months but not at month-12. eGFR levels were comparable between cohorts at all time points. Rates of biopsy-proven acute rejection at 1-year were similar between groups. rATG showed no significant adverse effects and survival at 12-months was comparable between groups.


- Retrospective cohort analysis analyzing the impact of a renal-sparing strategy using basiliximab in conjunction with mycophenolate mofetil and corticosteroids from day 0 post-LT along with delayed introduction of tacrolimus vs tacrolimus, mycophenolate mofetil, and corticosteroids from the outset. The renal-sparing regimen was associated with significantly lower incidence of all-stage AKI at day 7 post-LT and less decline in renal function at 3 months. No further significant differences in renal outcomes were observed at other time points on follow-up to 1 year post-LT.


- Single-center, retrospective case-control study evaluating AKI in liver transplant recipients receiving delayed CNI delayed CNI protocol (study group) vs. immediate CNI protocol (control
Patients with fulminant liver failure and who had already been on renal replacement therapy were excluded. Study group patients (n=30) received steroid induction, mycophenolate mofetil was added at the prescriber’s discretion, and CNI administration was delayed 48 to 72 hours. The control group (n=30) received CNI, MMF, and steroid induction and the CNI and MMF were continued posttransplant.

- AKI developed in 11 patients in the study group and in 20 patients in the control group (37% vs 66.7%; P = 0.02). There was no acute rejection observed in the first month in either group.


- Retrospective review of 3754 first-time liver transplant recipients comparing overall survival based on induction regimens grouped by steroid-only induction, use of antithymocyte globulin (ATG), or interleukin 2 receptor antibody. Compared with a steroid-only induction regimen, the addition of ATG is associated with worse overall survival after liver transplant for acute liver failure.


- Retrospective review of 20 adult primary living-donor transplant recipients to evaluate recipient safety, tolerability, and pharmacokinetics of mycophenolate mofetil suspension compared with mycophenolate mofetil capsules as part of induction therapy after living-donor liver transplant. Mycophenolate mofetil suspension at 3000mg/day resulted in significantly higher AUC plasma concentration compared to capsules without increasing the risk for adverse events or rejection.


- Cochrane review of 25 randomized clinical trials evaluating induction regimens (glucocorticoids, anti-thymocyte globulin, basiliximab, daclizumab, alemtuzumab, or no induction) in liver transplant recipients. Low-certainty evidence suggests basiliximab induction reduces mortality and graft failure compared with corticosteroid induction.


- Retrospective review comparing non-depleting induction vs depleting induction in 69,349 liver transplant recipients utilizing UNOS data. Only non-depleting induction was associated with a reduction in acute rejection. Both forms of induction were associated with a reduction in patient and graft loss, however, absolute difference was minimal.


- This retrospective review of 210 liver transplant recipients from 2007 through 2015 at New York Presbyterian Hospital/Columbia University assessed the impact of delaying CNIs with use of basiliximab induction on renal function between 4 groups with varying degrees of AKI
posttransplant. By delaying therapeutic CNI (therapeutic levels of 6-10) by about 14 days posttransplant in all 4 groups with varying degrees of AKI, there was no difference in renal function past 90 days posttransplant.


- This is a randomized controlled trial comparing tacrolimus monotherapy (TAC, n = 109) and tacrolimus plus a single, intraoperative, high-dose (9mg/kg), rabbit anti-T-lymphocyte globulin. The primary endpoint evaluated was immunosuppression minimization to monotherapy with other endpoints including biopsy-proven rejection, clinical rejection, and patient and graft survival.


- Meta-analysis of 6 randomized controlled trials conducted from 1998 – 2015 examining the use of basiliximab induction in liver transplant recipients vs. steroid induction alone. Basiliximab induction was found to significantly reduce the incidence of post-transplant diabetes, in addition to lower observed rates of hypertension and biopsy prove acute rejection.


- MEDLINE literature search involving 9 studies reviewing the use of rabbit antithymocyte globulin (rATG) induction therapy in liver transplant recipients. Patients receiving rATG induction tended to have improved renal function compared with patients not receiving induction. Rejection rates tended to be lower in recipients administered rATG.


- This retrospective review of 788 liver transplant patients studied the relationship between acute cellular rejection (ACR) and various clinical factors. Liver transplant recipients with older age, chronic hepatitis B virus infection, living donor liver transplantation and use of interleukin-2 receptor antagonist on induction have fewer ACR.


- This report demonstrated the benefits of a steroid-free immunosuppression protocol using rabbit antithymocyte globulin (RATG) induction in orthotopic liver transplantation (OLT) with tacrolimus minimization 500 recipients


- This single center study used a Multivariable analysis demonstrating induction agents to be independently associated with graft survival and ischemic cholangiopathy free graft survival when analyzed against variables including donor age, fWIT, donor cold ischemia time and transplant era.
- This study evaluated the 1- and 2-year patient survival and HCV recurrence rate in patients receiving ATG during the induction phase of immunosuppression after liver transplantation.

- This study reviewed the role of induction immunosuppression in positive crossmatch in liver transplantation. With the use of rabbit anti-thymocyte globulin ± rituximab induction, overall low rejection rates can be achieved in positive crossmatch liver transplantation.

- Cochrane review of 19 randomized clinical trials assessing immunosuppression with T-cell specific antibody induction compared with placebo, no induction, or another type of antibody induction in liver transplant recipients.

- Cochrane review of 10 randomized clinical trials assessing immunosuppression with T-cell specific antibody induction versus corticosteroid induction in liver transplant recipients.

- A review of antibody induction agents in liver transplantation, particularly the use of basiliximab in adults with renal function impairment allowing for delayed introduction of calcineurin-inhibitors.

- Review of rationale, mechanisms, safety and evidence supporting various induction agents used in liver transplantation. Includes tables summarizing RCTs on induction.

- Comparison of induction with tacrolimus + daclizumab vs. tacrolimus + steroids. Primary endpoint, median HCV viral load at 12 months, was similar between groups.

- Retrospective, single-center study comparing 3 induction methods: 1) rATG given in OR (n=166), 2) rATG given 48 hrs post-transplant (n=266), and 3) rATG given 48 hrs post-transplant + rituximab given 72 hrs post-transplant. No significant difference in 5-year survival was found between groups.

- Retrospective study in 184 LDLT patients who received either rATG or basiliximab for induction. Results showed significantly lower rates of rejection but higher rates of HCV recurrence in the rATG group.


- Prospective RCT in 295 HCV patients comparing steroid-free induction (tacrolimus + mycophenolate mofetil + daclizumab) to tacrolimus + steroids and tacrolimus + mycophenolate mofetil + steroids. No significant differences found in ACR, HCV recurrence, patient survival, or graft survival at 2 years.


- Retrospective case-control study comparing induction with alemtuzumab (n= 55) vs tacrolimus + steroid taper (n= 85). Alemtuzumab was associated with less hypertension and rejection but a higher rate of infections (due to increased number of viral infections). No significant differences in graft survival, patient survival, ACR, or renal dysfunction.


- Explores novel molecular targets for induction and maintenance immunosuppression, including CNI- free regimens.


- Comparison of thymoglobulin induction (n=44) or no induction (n=49). No difference found in ACR or long-term survival, but higher rate of leukopenia in thymoglobulin group.


- Retrospective study comparing rATG induction and delayed CNI initiation (n=118) versus early initiation of CNI (n= 80). All patients received MMF and steroids. Patients in the rATG group had significantly lower serum creatinine and a trend toward lower rates of ACR at 12 months post-transplant.


- HCV patients were randomized to receive either rATG (n=33) or methylprednisolone (n=31) induction. No significant difference was shown in patient survival or HCV recurrence rates at 6 months post-transplant.
- Review of induction and maintenance immunosuppressant strategies, focusing on potential for CNI sparing regimens.

- First reported RCT comparing induction with rATG (n=36) versus methylprednisolone (n=35). Showed a trend toward lower rates of ACR, post-transplant diabetes and HCV recurrence in the rATG group.

3.2 Maintenance therapy

3.2.1 Calcineurin Inhibitors
- Multi-center study assessing development of de novo donor-specific HLA antibody (dnDSA) and allograft histopathological abnormalities in liver transplant recipients on CNI-free maintenance regimens. A total of 727 liver transplant recipients undergoing initial liver transplant had protocolized follow-up with dnDSA screening and allograft biopsy (at 1, 5 and 10 years).
- CNIs were withdrawn in 166 (22.8%) patients with or without conversion to mammalian target of rapamycin inhibitors and/or maintenance with mycophenolic acid. DSAs were present after withdrawal in 30.1% (50/166) patients on CNI-free immunosuppression vs. 16% (90/561) on CNI maintenance therapy (p < 0.001). Cumulative incidence of dnDSA 10 years after transplant was 20% in the CNI group vs. 28% in the CNI-free group (p < 0.01). dnDSAs were associated with histological graft abnormalities (significant allograft fibrosis or rejection) (HR 2.24, 95% CI 1.2-4.1; p = 0.01) but a CNI-free regimen did not impact graft histology in univariate Cox regression analysis.

- Single-center, prospective, non-randomized, single-arm 24 month observational study evaluating changes in adherence to immunosuppressive medications as well as efficacy and safety after conversion of stable liver transplant recipients from twice-daily immediate release Tacrolimus (IR-Tac) to a novel once-daily Tacrolimus (LCP-Tac) formulation. Medication adherence was evaluated using the BAASIS® (Basel Assessment of Adherence Scale to Immunosuppressives) questionnaire and a Visual Analog Scale (VAS) at specified intervals. Data on tacrolimus troughs, adverse events, and acute rejection or graft loss during the study were recorded.

- This prospective study analyzed graft function, drug compliance, and adverse reactions after switching regimen from twice-daily to once-daily tacrolimus in 101 stable liver transplant recipients for 24 weeks. No acute rejection was seen within 24 weeks as well as no chronic
rejection, fatal deterioration of liver function, or death in any patient during the study period. After conversion, the trough level of tacrolimus decreased, and the mean ± standard deviation differences between the trough level and baseline level were 1.46 (±2.41) ng/mL, 0.43 (±2.08) ng/mL, and 0.07 (±2.73) ng/mL at 3, 12, and 24 weeks after conversion, respectively.


- Retrospective longitudinal study (n=127) investigating the association of tacrolimus blood levels with clinical outcomes late acute cellular rejection, death, patient survival and graft survival in patients undergoing liver transplantation. Increased risk of graft loss associated with increased standard deviations of tacrolimus blood levels may indicate the need for more rigorous and prospective monitoring of tacrolimus blood levels.


- 5-y, prospective follow-up of a large patient cohort (n = 856) from the 24-wk DIAMOND study evaluating long-term graft survival in liver transplant recipients treated with prolonged-release tacrolimus-based immunosuppression. Renal function, graft survival, and patient survival were similar between treatment arms at 5 y posttransplant.


- Retrospective study evaluating liver transplant recipients converted from immediate-release tacrolimus to extended-release tacrolimus. Among patients who switched formulations due to tremors, 88% noted significant improvement. No difference in SCr or GFR from baseline to 3 months post conversion and no episodes of ACR or CMV post conversion were seen.


- Retrospective study of 191 living donor liver transplant recipients evaluating factors contributing to post-transplant eGFR changes. Tacrolimus trough level was associated with eGFR changes 1 year after LDLT. The adjusted dose of tacrolimus and combined use of other immunosuppressants may be important to maintain renal function after transplant.


- Single-center, prospective sequential cohort analysis comparing clinical outcomes of liver transplant recipients receiving tacrolimus IR or de novo tacrolimus ER (Astagraf XL). Tacrolimus ER was associated with a reduction in new-onset CKD stage 3-4 compared with tacrolimus IR. Incidence of biopsy-proven acute rejection, patient and graft survival were similar between groups.

- Single-center retrospective review evaluating outcomes of early tacrolimus monotherapy (<6 months post-transplant) in 100 liver transplant recipients. Compared with patients transitioned to monotherapy after 6 months post-transplant, there were no differences in rejection, CMV infection, renal impairment, or patient survival at 5 years follow-up.


- Retrospective analysis of European Liver Transplant Registry of long-term liver transplantation outcomes with prolonged-release tacrolimus (Astagraf) versus immediate-release tacrolimus-based immunosuppression. Analysis comprised up to 8-year data collected in an extension of the previously published ELTR study.


- This is a phase 4 single-arm open-label prospective study assessing the efficacy and safety of conversion from twice-daily tacrolimus to once-daily prolonged-release tacrolimus in living donor LT recipients. Adherence was evaluated during outpatient visits after tacrolimus conversion, as well as acute rejection, graft loss, or patient death after Tac conversion


- Randomized, open-label, comparative, single-center, Phase 4, 24-week study comparing pharmacokinetics, safety, and efficacy of once-daily, prolonged-release tacrolimus with twice-daily, immediate-release tacrolimus in adult de novo living-donor liver transplant recipients in Korea.


- Multicenter, prospective, randomized, trial evaluating fibrosis development 12 months post-transplant for hepatitis C virus cirrhosis in 356 liver transplant recipients receiving either cyclosporine or tacrolimus. Fibrosis score >2 at month 12 was similar among both groups.


- The prospective, randomized, multicenter trial evaluated the impact of reduced-dose tacrolimus in combination with mycophenolate mofetil (experimental) compared to standard dose tacrolimus (control) in 195 liver transplant recipients. Rate of acute graft rejection and occurrence of renal dysfunction, arterial hypertension, or diabetes were lower in the experimental group.

- Prospective, randomized trial evaluating standard dose tacrolimus in combination with corticosteroids (n=183); reduced-dose tacrolimus, mycophenolate mofetil (MMF), and corticosteroids (n=170); and daclizumab induction with delayed introduction of reduced-dose tacrolimus, MMF, and corticosteroids (n=172) in liver transplant recipients who were without renal dysfunction in the pre-transplant setting. Estimated glomerular filtration rate decreased the least in the daclizumab induction group. Patient and graft survival were similar among all groups.


- Liver transplant recipients with chronic renal dysfunction are randomized to receive either calcineurin inhibitor therapy (N=30) or mycophenolate mofetil (MMF) in combination with reduced dose calcineurin inhibitor therapy (N=60). Serum creatinine significantly decreased and estimated glomerular filtration rate increased in the MMF group.


- Randomized, multicenter trial evaluating tacrolimus compared to cyclosporine maintenance therapy in 529 liver transplant recipients. Biopsy-proven acute rejection at one year following transplant was significantly lower in the tacrolimus group. There was no difference in patient survival at 5 years following transplant.

3.2.2 Antimetabolites


- Investigated the effects of Tacrolimus and mycophenolate mofetil (MMF) on the inhibitory function of Tregs and explored the regulatory mechanism in patients after liver transplantation. Tacrolimus and MMF enhanced the function of Tregs by synergistically affecting PD-1 and TIGIT in liver transplant patients.


- Cohort study of 1250 LTRs with HCC on the impact of mycophenolate on HCC recurrence. Increased HCC recurrence rates were observed (p = 0.03) following MMF administration; no significant increase was demonstrated following cyclosporine, tacrolimus, or sirolimus administration. Significantly increased HCC recurrence rate following MMF administration with cumulative defined daily dose (cDDD) > 0.4893 compared with cDDD ≤ 0.4893 or no administration of MMF (p < 0.0001).

This review aimed to evaluate the effectiveness and safety of tacrolimus associated with mycophenolate mofetil (MMF) in patients undergoing liver transplantation. Eight randomized trials were included. Patients undergoing liver transplantation who received tacrolimus plus MMF had similar adverse events when compared to patients receiving other evaluated immunosuppressive regimens and had a lower risk of acute rejection than those receiving in the monodrug tacrolimus regimen.


Retrospective review of adult liver transplant recipients at a Spanish center evaluating malignancy rates in patients maintained a mycophenolate monotherapy regimen. Patients converted to an immunosuppression regimen of mycophenolate monotherapy experienced less de novo malignancy, non-melanoma skin cancer and other malignancies compared to recipients with maintenance immunosuppression with calcineurin inhibitors.


The prospective, randomized trial evaluates maintenance immunosuppression consisting of either calcineurin inhibitor monotherapy or mycophenolate mofetil (MMF) monotherapy in 150 liver transplant recipients. Although no significant difference in acute rejection was identified between groups, the MMF monotherapy group had a trend to higher rejection rates. Chronic rejection was absent in both study groups and 5-year survival was similar among both groups.


Randomized double-blind trial evaluating liver transplant recipients treated with MMF (n = 278) or AZA (n = 287), both in combination with cyclosporine and corticosteroids. The incidence of acute rejection or graft loss was significantly higher in AZA patients (47.7% vs 38.5%, p <0.03) Steroid-resistant rejection occurred in 8.2% of AZA patients versus 3.8% in MMF patients (P <.02). Patient and graft survival rates at 1 year posttransplantation were similar.

3.2.3 mTOR Inhibitors


Retrospective study evaluating 303 liver transplant recipients to investigate whether everolimus (EVR) affects long-term survival after liver transplantation (LT) in patients with hepatocellular carcinoma (HCC). Combined with CNIs, EVR has the potential to prolong long-term survival in patients undergoing LT for HCC.


Data from 2 randomized liver transplant trials (N = 772; H2304 [deceased donor, n = 488], H2307 [living donor, n = 284]) were pooled to further evaluate the efficacy and safety of everolimus with reduced tacrolimus (EVR + rTAC) versus standard tacrolimus (sTAC) regimen at month 24. EVR
rTAC versus sTAC showed comparable efficacy and safety with significantly better renal function, particularly in patients with normal/mildly decreased renal function (CKD stage 1/2) at randomization and a trend toward lower HCC recurrence in patients transplanted with HCC beyond Milan at month 24.


- Prospective, randomized, open-label trial comparing everolimus (EVR) and mycophenolic acid (MPA) with CNI and MPA immunosuppression. EVR with MPA resulted in significant long-term improvement in renal function and quality of life at 24 months after liver transplantation compared with standard CNI with MPA immunosuppression.


- Data from 508 patients of the intention-to-treat SiLVER-trial analysis were included in exploratory univariate and multivariate models for overall survival (OS), DFS and a competing risk analysis for HCC recurrence. mTOR-inhibitor treatment with sirolimus for ≥3 months improves outcomes in LT for HCC, especially in patients with alpha-fetoprotein-evidence of higher tumor activity, advocating particularly for mTOR inhibitor use in this subgroup of patients.


- Single-center, retrospective study evaluating renal function of 66 liver transplant recipients who received de novo everolimus in combination with tacrolimus minimization or withdrawal for baseline renal dysfunction. With 24 month follow-up, eGFR was significantly and persistently greater than baseline eGFR.


- Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.


- Two-year follow up of the SIMCER trial (early conversion from CNI to everolimus in combination with mycophenolate and prednisone). Continuation of everolimus was associated with preservation of renal function, however, only approximately 50% of patients were able to continue to everolimus therapy due to safety or efficacy concerns.

● Randomized multicenter, open-label study evaluating 284 living-donor liver transplant patients
starting everolimus + reduced tacrolimus or continue standard tacrolimus. The primary endpoint
was treated BPAR, and graft loss or death at 12 months posttransplant.

Less Weight Gain Than Tacrolimus 2 Years After Liver Transplantation: Results of a Randomized

● Randomized multi-center study of patients in one of the following groups (1) everolimus +
reduced tacrolimus (2) tacrolimus control (3) Tacrolimus elimination. Post hoc analysis
completed evaluating weight change at 12 and 24 months, as well as vital signs, lipids, and
laboratory parameters at 12 and 24 months.

With Early Tacrolimus Withdrawal After Liver Transplantation: A Multicenter Randomized Trial (SIMCER).

● Randomized multi-center open-label trial of de novo liver transplant recipients receiving either to
everolimus with low-exposure tacrolimus discontinued by month 4 or to tacrolimus-based therapy,
both with basiliximab induction and enteric-coated mycophenolate sodium with or
without steroids. Everolimus was associated with a significant improvement in renal function
compared with CNI at 28 weeks post-transplant, however, a higher incidence of treated biopsy-
proven acute rejection was observed.

function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver

● Five-year follow up of the PROTECT study (early conversion from CNI to everolimus vs CNI).
Conversion to everolimus resulted in better renal function and comparable patient and graft
outcomes with long-term follow up.

Sterneck M, et al. (2014). Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a

● Prospective, randomized trial in 203 liver transplant recipients receiving either everolimus with
corticosteroids or cyclosporine/tacrolimus with corticosteroids. Glomerular filtration rate was
significantly higher in the everolimus group by month 35 following randomization. No difference
in biopsy-proven acute rejection, graft loss and death was seen between groups.

Asrani SK, et al. (2014). De novo sirolimus and reduced-dose tacrolimus versus standard-dose
tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. American

● Phase II, multicenter, randomized trial in 222 liver transplant recipients who received either standard-dose tacrolimus with corticosteroids or sirolimus, reduced-dose tacrolimus, in
combination with corticosteroids. Patient and graft survival were significantly lower in the
sirolimus group. Similar rates of acute cellular rejection were seen among both study groups.

Hepatocellular Carcinoma After Failure of Sorafenib: The EVOLVE-1 Randomized Clinical Trial. JAMA.
Everolimus, 7.5 mg/d, or matching placebo, both given in combination with best supportive care and continued until disease progression or intolerable toxicity. Per the 2:1 randomization scheme, 362 patients were randomized to the everolimus group and 184 patients to the placebo group. Everolimus did not improve overall survival in patients with advanced hepatocellular carcinoma whose disease progressed during or after receiving sorafenib or who were intolerant of sorafenib. Teperman L et al. (2013). Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial. Liver Transplantation, 19(7), 675-89. Retrieved from: http://www.ncbi.nlm.nih.gov/pubmed/23775875.

Mycophenolate mofetil (MMF) and sirolimus combination therapy (n=148) is compared to MMF and calcineurin inhibitor (CNI) combination therapy (n=145) for preserving renal function in liver transplant recipients. The sirolimus group had a significantly greater improvement in glomerular filtration rate and increased rates of biopsy-proven acute rejection compared to CNI group. Patient survival was similar between both groups. Saliba F, et al. (2013). Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. American Journal of Transplantation, 13(7), 1734-45. Retrieved from: http://www.ncbi.nlm.nih.gov/pubmed/23714399.


Prospective, multicenter, open-label study comparing three immunosuppression regimens in de novo liver transplant recipients: (i) everolimus with tacrolimus elimination, (ii) everolimus with reduced-exposure tacrolimus, and (iii) standard exposure tacrolimus. Group ii and iii had a similar composite outcome of treated biopsy proven acute rejection (tBPAR), graft loss or death at 12 months but group ii had less tBPAR than group iii. Group ii had improved GFR compared to group iii but had more discontinuation due to adverse events. Asrani SK, et al. (2010). Use of sirolimus in liver transplant recipients with renal insufficiency: a systematic review and meta-analysis. Hepatology, 52(4), 1360-70. Retrieved from: http://www.ncbi.nlm.nih.gov/pubmed/20815021.

Eleven randomized controlled trials and observational trials are included in the meta-analysis to evaluate the impact of sirolimus on renal function in liver transplant recipients. Sirolimus use was associated with improved renal function. Sirolimus use was not associated with patient death, graft failure, and rejection.

3.2.4 Co-Stimulation Blockade

- Retrospective review of 8 patients who underwent kidney after liver transplant and were treated with belatacept-based immunosuppression and transient CNI therapy. All patients tolerated belatacept therapy without any patient deaths or graft losses. No episodes of rejection, de novo donor-specific antibody formation, or major systemic infections were observed, and all patients demonstrated preserved liver and excellent renal allograft function.


- Phase II RCT evaluating de novo belatacept in liver transplant recipients. Patients were randomized to one of five treatment arms (1. basiliximab + belatacept high dose [HD] + mycophenolate mofetil [MMF], 2. belatacept HD + MMF, 3. belatacept low dose [LD] + MMF, 4. tacrolimus + MMF, or 5. tacrolimus alone). Due to an increase in death and graft loss with belatacept users, the study was terminated early after 12 months.


- Retrospective review evaluating the use of belatacept at a single center in seven liver transplant recipients with hepatitis C virus. Patient survival, graft survival, and biopsy-proven acute rejection episode are among the endpoints evaluated.

3.2.5 Other


- Review of evidence evaluating the impact of immunosuppression agents on hepatocellular cancer recurrence and oncological survival.


- The current study analyzes the Scientific Registry of Transplant Recipients Database to identify risk factors for mortality and graft loss in liver transplant recipients with or without hepatitis C virus indication for transplant.


- Prospective, randomized, multicenter trial evaluating tacrolimus and corticosteroid (N=77); tacrolimus, corticosteroid, and mycophenolate mofetil (N=72); and daclizumab induction with tacrolimus and mycophenolate mofetil (N=146) in liver transplant recipients. No difference in acute cellular rejection, hepatitis C virus recurrence, or patient/graft survival was found among all study groups.

3.3 ABO-Incompatible Liver Transplantation

- Case report of 48-year-old male patient with blood group type B who underwent ABO-incompatible liver transplant of a right lobe liver graft from a type A2 living donor. The recipient's anti-A isohemagglutinin (AAI) titers were checked preoperatively and were serially measured on a daily basis postoperatively. Immunosuppression included tacrolimus, MMF, and corticosteroids. Authors describe AAI titer trend and management of subsequent severe acute AMR which included conventional therapeutic plasma exchange (TPE), immunoadsorption, and splenectomy.


- Single-center evaluation of outcomes in 20 ABOi DDLTs using the center’s antibody reducing immunosuppressive protocol for patients in urgent need of liver transplant. There were 12 non-A2 donors (A1=8, B = 3, AB = 1) and 8 A2 donors. Immunosuppression consisted of rituximab (n = 20) and basiliximab (n = 15) or anti-thymocyte globulin (n = 4), intravenous immunoglobulin (IVIG; n = 6), tacrolimus, prednisolone and mycophenolate mofetil. Fifteen patients were treated with IA (antigen specific immunoadsorption; n = 14) or both IA and plasmapheresis (PP; n = 1) pre-transplant and 18 patients were treated with IA (n = 15) or both IA and PP (n = 3) post-transplant. Patient and graft survival and complications were compared to a 1:4 case matched control group of ABO-identical or compatible (ABOi/c) DDLT. The 1-, 3- and 5-year patient and graft survival rates were 85, 85 and 78% for the ABOi recipients and not significantly different compared to ABOid/c controls. Only one ABOi patient developed antibody-mediated rejection.


- Meta-analysis based on observational studies that included outcomes at at least 1 year for 2137 ABOi-LT and 8646 ABOc-LTs. The short-term and long-term outcomes were worse after ABOi-DDLT than ABOc-DDLT in the all-cause mortality, death-censored graft survival, and complication incidence rate. However, the same outcomes were essentially comparable between ABOi-LDLT vs. ABOc-LDLT cohorts.


- Retrospective review of 20 ABO-incompatible living donor liver transplant cases that utilized rituximab 2-3 weeks prior to transplant, subsequent plasma exchanges, basiliximab administration, and IVIG protocol. No patients had biopsy-confirmed antibody-mediated rejection. No bacterial or fungal infections were observed. Biliary anastomotic stricture was observed in 9 patients.

● Retrospective review of 71 pediatric liver transplant recipients of ABO-incompatible grafts who received management with IVIG and/or plasmapheresis pending anti-ABO titer levels. Compared with ABO-compatible transplant recipients, there were no differences in surgical complications, graft or patient survival at 3-year follow-up.


● Systematic review and meta-analysis of 9 studies (retrospective or prospective) evaluating the safety and effectiveness of rituximab in ABO-incompatible living donor liver transplantation. No differences were observed when comparing graft or patient survival at 1, 3, or 5 years' post-transplant for ABOi vs ABOc groups, however, ABOi transplant recipients had higher rates of biliary complications, CMV infection and AMR.


● Systematic review and meta-analysis of 21 retrospective studies including 8247 total patients (1494 ABO-incompatible and 6753 ABO-compatible liver transplant recipients). ABOi transplant recipients were noted to have lower 1, 3, and 5-year graft survival, as well as an increased incidence of AMR, chronic rejection, CMV, and surgical complications, as compared to ABO-compatible recipients.


● Forty-seven ABO-I LDLT procedures were included. Ninety-four patients who had ABO-C LDLT were selected as a comparator group. The incidence of cytomegalovirus, bacterial and fungal infections during the first 3 months was similar after ABO-I LDLT and ABO-C LDLT. The 1-, 2- and 3-year patient survival rates after ABO-I LDLT and ABO-C LDLT were 89% vs 87%, 85% vs 83%, and 85% vs 79% respectively.


● Retrospective review of 235 adult patient undergoing adult donor living donor liver transplantation. The desensitization protocol included a single dose of rituximab and total plasma exchange. Three-year graft and patient survival rates were comparable to those of the ABOc group, however, 17 patients experienced AMR that manifested as diffuse intrahepatic biliary stricture; six cases required retransplantation, and three patients died.


● Study showing B-cell and T-cell immune responses in both KT and LT recipients. Investigated the kinetics of proportions of peripheral blood B-cell subsets in transplant recipients to compare the susceptibility to rituximab of ABO-I KT and LT. Rituximab has differing B-cell sensitivity between KT and LT recipients and a minimal effect on the alloreactive T-cell responses in KT and LT recipients.

Five year follow up study of 19 patients receiving ABOi-LDLTs using plasmapheresis and rituximab for desensitization. ABOi-LDLTs had increased incidence of cytomegalovirus infection (52.6% vs. 22.9%), other post-transplant complications including bacterial sepsis and acute rejection were not different. The 5-year graft survival rate was 87.9% in ABOi-LDLTs and 80.3% in non-ABOi-LDLTs.


Retrospective review of 22 patients with severe Hepatitis B(SHB) in whom were performed emergency liver transplantation from ABO-incompatible donors. Although the 1-, 3-, 5-year graft and patient survival rates of ABOi were lower than that of ABO-compatible group, the results suggested that ABOi liver transplantation might be a life-saving procedure for patients with SHB as a promising alternative operation when ABO-c donors are not available and bridges the second opportunity for liver retransplantation.


Review of changes in treatment strategies in ABOi LDLT for acute liver failure. The desensitization protocol for ABOi barrier included Case #1; local infusion + plasma exchange (PE), Case #2; local infusion + rituximab + PE, Case #3 and #4; rituximab + PE, and Case #5; rituximab + PE under high-flow continuous hemodiafiltration. The patients of Case #2 and #3 received rituximab within 7 days before LDLT and experienced antibody-mediated rejection. Rituximab-based ABOi-LDLT given at least 2 weeks prior to transplant, most-recently under high-flow hemodiafiltration for treating encephalopathy, is a feasible option for applying LDLT for ALF.


A retrospective review of the literature highlighting results in ABO-incompatible deceased donor liver transplantation in adult recipients. Both groups conclude that ABOi DDLT might be life-saving and might be used in urgent cases.


Uncontrolled, retrospective, observational study in 61 patients receiving ABOi LT. Results show non-A2 grafts are associated with inferior graft survival and increased risk of rejection, vascular and biliary complications. ABOi LT performed with A2 grafts is associated with good long-term graft survival and can be used safely in urgent cases.


Uncontrolled, retrospective, observational study in 381 ABO-incompatible living-donor liver transplant (LDLT) recipients comparing desensitization with or without rituximab. Rituximab was associated with significantly lower rates of antibody-mediated rejection (AMR).


- Overview of use of apheresis, including management of associated complications.


- Review article describing mainly progress in ABO-incompatible liver transplant since 1998, highlighting improved survival seen since the introduction of rituximab prophylaxis in 2003.


- Analysis of UNOS data in ABO-incompatible liver transplants from 1990-2006 (N= 667 adults; N= 326 infants/ pediatrics), identifying trends that may be useful in guiding allocation of incompatible organs.


- Report of 5 ABO-incompatible LDLT recipients treated with plasmapheresis and IVIG pre-transplant, followed by thymoglobulin induction splenectomy. At 43 months post-transplant, 4 of 5 patients were alive with their original grafts. The 5th patient died of multi-organ failure 4 months after transplant; cause of organ failure was not determined. Overall results suggest favorable outcomes in ABO-incompatible LDLT.


- Prospective study in 30 ABO-incompatible LDLT patients treated with hepatic artery infusion (HAI) only or HAI with rituximab prophylaxis. Rituximab was associated with a trend toward lower rates of humoral rejection and lower peak IgG titers.


- Retrospective study of 14 ABO-incompatible liver transplants treated with a protocol including total plasma exchange pre- and post-transplant, splenectomy at time of transplant and quadruple immunosuppression. Five-year patient and graft survival rates were 71.4% and 61.2%, respectively. No antibody-mediated rejections occurred.

3.4 Management of Rejection


- Case series of 5 LTs developing biopsy-proven ACR following COVID-19 vaccination (3 received Moderna 2 received Pfizer-BioNTech). Two patients had a history of ACR at 40 days and 418 days post-LT (195 and 370 days prior to the first dose of vaccination, respectively). Three patients had elevation in liver enzymes after the first dose of vaccination but they eventually received a second dose without complication and all patients completed their vaccination series.

- Three patients had RAI 5 out of 9 and the other 2 had 3 out of 9 and 2 patients required admission for ACR treatment. All patients were initially treated with high dose IV methylprednisolone for 3 days and 3 patients started on additional immunosuppressive medications. Liver enzymes returned to normal (or baseline) in all patients. No patients required
readmission to hospital, died or developed graft failure and no patients developed symptomatic COVID-19 infection during the follow-up period after vaccination and treatment of ACR.


- Systematic review performed to identify immunosuppression regimens to minimize early ACR following LT and provide expert panel recommendations. Studies from January 2000 onward focusing on early ACR were included. Rates of early renal dysfunction and infection were evaluated. Thirty-seven studies met inclusion criteria (23 randomized controlled trials, 14 retrospective or prospective observational comparative or noncomparative studies). Several sources of biases which potentially confound conclusions were identified: heterogeneity in immunosuppression protocols, higher serum tacrolimus levels than currently used in clinical practice, differences in the definition of ACR. Expert panel recommendations are provided based on review of included studies.


- Case report of living donor liver transplantation (LDLT) complicated with severe acute antibody-mediated rejection (aAMR) despite desensitization with rituximab and plasma exchange before LDLT for preformed donor-specific anti-human leukocyte antigen antibody (DSA). Immunosuppressive regimen included steroids and tacrolimus. Re-administration of rituximab followed by 4 courses of plasma exchange failed to treat aAMR. The DSA mean fluoro-intensity was successfully suppressed after bortezomib was administered however impaired serologic liver function test and cholestasis remained. LFTs and cholestasis in the graft were improved after everolimus was administered and the recipient was discharged on POD196.


- Review of recent progress in the field of biomarker discovery in liver allograft rejection. Developments include blood genomic assays measuring miRNA, mRNA and donor-derived cell-free DNA. Additionally, serum levels of cytokines, proteoforms, donor-specific antibodies and immunophenotyping have shown promising results in predicting rejection pre and/or posttransplant. The findings discussed in the studies outlined in the review are promising in the potential to improve patient management, reduce complications from over- or under-immunosuppression, and ultimately enhance outcomes.


- A 10-year, single-center, retrospective cohort study describing steroid-resistant rejection (SRR) and steroid-sensitive rejection (SSR) and comparing the effect of the SRR treatment methods. Of 663 cases, 124 patients (18.7%) with biopsy-proven rejection were analyzed. Multivariate
analysis was performed on risk factors of SRR at first rejection. CMV infection and total bilirubin at first rejection and numbers of rejection were significant results. Both overall survival and allograft survival rate of SSR are higher than SRR (P < .001). Of second-line treatment patients, 13 patients (54.2%) recovered, and 11 patients (45.8%) failed to recover. Survival was the highest in patients using antithymocyte globulin and in patients with liver retransplantation.

- Discusses recent studies with preliminary results regarding utilizing non-invasive biomarkers such as quantification of dd-cfDNA, mRNA microarray profiling of differentially expressed genes, and characterization of cytokine responses and immunophenotypic shifts to aid in diagnosis and treatment of allograft rejection.

- Review article discussing the recent advances in the clinical diagnosis and treatment of antibody-mediated rejection in liver transplantation, as well as some of the histopathologic features (on liver biopsy tissue) of acute and chronic antibody mediated rejection.

- A literature review of 24 case series containing 64 liver transplant recipients with antibody-mediated rejection investigating treatment management for mild and moderate to severe acute antibody-mediated rejection.

- Multi-center, retrospective analysis of 142 liver transplant recipients with preformed DSAs evaluating impact of induction therapy and transplant outcomes. Preformed DSA was associated with significantly higher rates of acute rejection but not patient survival.

- Review article of the impact of pre-formed donor specific antibodies and de novo anti-human leukocyte antigen donor-specific antibodies in liver transplantation, as well as strategies to overcome the issue.

- Recommendations of the International Liver Transplantation Society (ILTS) Consensus guidelines on T-cell mediated rejection and antibody mediated rejection in liver transplant recipients are presented in this consensus findings article.

- This article reviews prevention and treatment strategies for acute and chronic antibody-mediated rejection (AMR).


- This article reviews the implications and impact of preformed and de novo DSAs in liver transplantation and outlines potential management.


- This article addresses the concerns surrounding the misunderstandings of the role of donor specific antibodies in liver transplantation. Experts were consulted to pool common theories and clinical experience. The findings suggest that AMR is typically overlapped with ACR in liver transplantation and those patients undergoing simultaneous liver-kidney transplant are at higher risk for AMR post-transplant. DSA identification prior to transplant which persist post-liver transplant increase the risk for AMR as well.


- This article reviews the pathology of antibody-mediated rejection (AMR) focusing on recent studies which have improved our understanding of the clinicopathological features and diagnostic approaches.


- This review article focuses on the epidemiology, pathogenesis, treatment and the possible influence of rejection on the risk of recurrent disease in the liver allograft.


- 52 liver transplant recipients with hepatitis C were assessed for the incidence of, risk factors for, and outcomes of PEGIGD. PEG-IGD has high morbidity and mortality and is not associated with increased rates of virologic response and is recommended to be avoided due to an increased risk of rejection.


- Case report of three liver transplant recipients with ABO-compatible refractory AMR. Treatment with bortezomib resulted in normalization of liver function tests, resolution of C4d deposition and decrease in DSA.

Due to the controversy in utilizing steroids in liver transplant recipients experiencing rejection due to reactivation of diseases, basiliximab was studied. Authors concluded that basiliximab can be safely used as rescue therapy for ACR without significant adverse effects in patients who underwent liver transplantation for HCV cirrhosis.


This article addresses the differences between acute and chronic rejection with regard to pathophysiology and clinical presentation. A discussion on antibody-mediated rejection is also present in this review.


This review article discusses risk factors for acute rejection and different management strategies from different transplant centers. The reported incidence of acute cellular rejection is also reported.

3.5 Hepatic Diseases
3.5.1 Acute Hepatic Necrosis

Authors used UNOS LT data to analyze severe herbal and dietary supplement (HDS)-induced acute liver injury in the US and identify epidemiologic differences between patients with HDS drug-induced liver injury (DILI) and non-HDS DILI. A subanalysis was performed for transplanted patients, including longitudinal changes. Of 1875 patients waitlisted, 736 (39.2%) underwent LT. The proportion of Asian patients in the HDS DILI group was significantly higher vs. the non-HDS DILI group (17.4% versus 3.8%; P < 0.001). Excluding acetaminophen cases, the proportion of Black patients in the HDS DILI vs. non-HDS group was significantly lower (8.7% versus 25.3%; P < 0.001). Waitlisted patients with HDS DILI were significantly older (median age, 38 years for HDS DILI versus 31 years for non-HDS DILI; P = 0.03). The number of patients requiring LT for HDS DILI increased significantly over time with >70% of cases occurring in the last 10 years (2010-2020) compared with the prior 15 years (1994-2009; Ptrend = 0.001). Ethnicity may help in identifying the cause of severe acute DILI, a growing problem as more patients experiment with HDS.


Review article discussing the role of liver transplant in acute-on-chronic liver failure including prognosis scores, critical care management of patients awaiting liver transplant, donor issues, and post-liver transplant outcomes in acute-on-chronic liver failure


Review article describing common causes, diagnosis, management, prognosis, as well as long-term outcomes after transplant. A brief review of available evidence is also included.
- Review article which focuses on etiologies of acute liver failure and the management of various complications. The role of liver transplantation in this population is also discussed.

- Study designed to estimate population rates of NSAID associated acute liver failure leading to transplantation. 9479 patients total across 52 centers were registered for transplantation with 600 of them actually leading to transplantation. Of these 600, 301 had received either NSAID or paracetamol therapy within 30 days of transplantation.

- 189 patients were randomized to receive molecular adsorbent recirculating system (MARS) or to standard medical therapy. No significant difference was seen between the two groups with respect to 28-day survival. When confounders were controlled, patients who received MARS also did not have a significantly beneficial effect over standard medical therapy. However, in patients with severe HE, MARS may have a role in decreasing the grade of diseases more rapidly than standard medical therapy without additional adverse effects.

- Guidelines review from the American Association for the Study of Liver Diseases. Etiology of acute liver failure and therapeutic management are discussed.

- Cases of idiosyncratic drug-induced liver failure are discussed. Long-term outcomes, such as transplant-free survival and overall survival are also discussed as well.

- 173 patients with non-acetaminophen induced acute liver failure were stratified to receive either intravenous NAC (N=81) or placebo (N=92). Overall survival was 70% in the NAC group and 66% in the placebo group (p=0.283). Transplant-free survival however, was significantly better in those that received NAC (40%) vs. those that received placebo (27%); p=0.043. This benefit was seen in patients with coma grades I-II, suggesting that more advanced coma grades (worse encephalopathy) did not benefit from NAC with regards to survival.

- Review article which discusses the epidemiology of acute liver failure secondary to acetaminophen toxicity. Overall survival, median dose ingested, and intentional vs. unintentional overdose data are discussed.
- Review article which discusses the incidence of viral-hepatitis induced acute liver failure. This article discusses the incidence of transplant free-survival rate as well as transplant rate differentiation between different subsets of viral hepatitis.

3.5.2 Biliary Atresia
- Retrospective cohort study comparing outcomes of pediatric candidates with biliary atresia listed for primary vs. salvage liver transplantation between March 2002 and February 2021 using the SRTR/OPTN database. Of 3,438 transplant candidates with biliary atresia listed for liver transplantation, 15% were listed for primary transplantation, 17% for salvage transplant after early Kasai failure, and 67% after late Kasai failure. Candidates listed after late Kasai failure had lower disease severity as demonstrated by lower bilirubin levels, lower MELD/PELD scores, and lower incidence of hospitalization at time of transplant in comparison to candidates listed for primary transplantation. Children with late Kasai failure had significantly superior waiting list and post-transplant graft survival compared to those that did not undergo Kasai hepatoportoenterostomy and were listed for primary liver transplantation. Candidates listed for primary liver transplantation and for salvage transplantation after early Kasai failure had equivalent waiting list and post-transplant survival outcomes. There were no differences in waiting list, recipient, or graft survival with primary vs. salvage liver transplant after early failure.

- This review article discusses conditions which favor native liver survival after Kasai procedure and the ones which optimize a positive liver transplant outcome. It also discusses pathophysiology of biliary atresia and transition of care.

- Multi-center study conducted of the first nationwide survey in Japan to assess the status of primary liver transplant for biliary atresia in over 2800 patients.

- Systematic review of liver transplantation for biliary atresia.

- This primary article observes the difference in outcomes in patients with biliary atresia who received steroid therapy vs. those that did not. 153 infants underwent portoenterostomy. Afterwards, patients were divided into three groups, low dose steroid (prednisolone 2mg/kg/day), high dose steroid (prednisolone 5mg/kg/day), and no steroids. A significant difference was seen
between groups with respect to decreases in bilirubin and AST between the high dose steroids vs. no steroid groups. There was also an increase in the clearance of jaundice between those patients that received steroids and those that did not. This study supports the use of steroids in infants immediately post portoenterostomy.


● This review article discusses the diagnosis and management of biliary atresia. The main points of discussion include pathophysiology, kasai’s procedure, and the role of liver transplantation.


● This clinical trial evaluated the use of steroids as adjuvant therapy after Kasai’s procedure. Patients were randomized to receive placebo or 2mg/kg/day of prednisolone on day 7 to 21 and then 1mg/kg/day on day 22 to day 28. There was a statistically significant difference in bilirubin levels with much lower levels seen in the steroid group at 1 month (66 vs. 92 mmol/L; p=0.06). However, no difference was seen at 6 months (p=0.56) or 12 months (p=0.3). The need for liver transplantation at 6 and 12 months was also not statistically significant (p=0.99, p=0.47, respectively). The authors concluded that the rates of reduction in bilirubin were only apparent in the immediate post-operative period (1 month), but did not sustain a long term effect.

3.5.3 Malignant Neoplasms


● Evaluated the impact on HCC recurrence of an immunosuppression protocol introduced in 2010 with interleukin-2 receptor antibody (IL-2RA) induction and delayed-introduction of reduced-dose tacrolimus with mycophenolate. A total of 235 patients (mean MELD 13, 57% within Milan criteria) were included. The cumulative 5-yr HCC recurrence rate in LT before and after 2010 were 28.6% and 19.7%, respectively. IL-2RA induction had no independent effect on HCC recurrence. High tacrolimus exposure (mean 20-day tacrolimus concentration ≥8ng/mL) was associated with increased HCC recurrence risk on univariable analysis (HR 2.22, 95% CI 1.23-4.01, p = .008), but was non-significant on multivariable analysis (p = .17). Outside Milan criteria, high tacrolimus exposure was significant for HCC recurrence (HR 3.68, 95% CI 1.34-10.11, p = 0.012) independently of tumor characteristics and AFP level. This was confirmed on multivariable propensity score-adjusted analysis. Further studies are needed to confirm if early tacrolimus-minimization strategies can help reduce HCC recurrence rates and help extend transplant criteria.


● Meta-analysis of 9 retrospective studies analyzing the effect of statins on recurrence of hepatocellular carcinoma after liver surgery. Findings suggest statins decrease the recurrence rate of hepatocellular carcinoma after liver transplantation or resection.
- Retrospective analysis of 72 liver transplants performed in response to hepatocellular carcinoma (HCC). HCC recurred in 7 patients (9.7%; 5 adult, 2 pediatric). Except for one patient, all were in the late diagnosis group. Mean survival in the early diagnosis group was longer than in the late diagnosis group. During follow-up, 11 patients died from recurrence and distant metastasis.

- Review article describing strategies to help refine selection criteria for liver transplant in patients with HCC, and post-transplant management

- A comprehensive PubMed/MEDLINE review of 120 studies that outlines the various selection criteria for LT, discuss the outcomes of LT in HCC patients, and explore future directions of LT for HCC

- This review discusses risk factors for HCC recurrence, surveillance modalities, HCC prevention and treatment strategies after liver transplantation.

- Systematic review and meta-analysis of 63 studies including pre-liver transplant patients with hepatocellular carcinoma. Reviews data available describing outcomes of various approaches to HCC management, including observation vs. therapy, transplant alone vs. transplant with bridging, and transplant without down-staging vs. transplant following down staging to within Milan Criteria.

- Extensive review of cholangiocarcinoma, including epidemiology, anticipated outcomes, standards of care based on anatomical subtype, surgical approach and consideration of transplant, use of newer immunotherapies, and emerging investigational therapies.

- Randomized, open-label study of 525 liver transplant recipients with hepatocellular carcinoma (HCC) randomized to maintenance immunosuppression incorporating either sirolimus or continuing standard of care. The primary endpoint of recurrence free survival (RFS) occurred in
218 (85.2%) of the treatment/sirolimus group and 233 (92.5%) of the control group at 1-year post-transplant (p=0.01). However, this difference became non-significant at 2–years. Benefit in RFS was most pronounced in those considered low-risk based on Milan Criteria.


- This review article serves as a reference for the diagnosis and clinical management of cholangiocarcinoma. Being the second most common primary hepatic malignancy worldwide, this article will provide a reference as to the common treatment strategies.


- This review article describes various strategies for managing hepatocellular carcinoma before and after liver transplantation. Treatment strategies such as radiofrequency ablation, transarterial chemoembolization, and other therapies are described in detail. Many primary articles are also referenced throughout this review. This will serve as a reference for those who wish to expand their exposure to standard management of HCC pre and post-liver transplantation.


- This review article describes criteria for liver transplantation in patients with HCC and discusses Milan criteria. Other areas discussed include living donor liver transplantation for HCC and expanding Milan criteria in the setting of an increased incidence of HCC. Many patients are unable to undergo surgical resection due to location of tumors or due to high perioperative mortality risk. This article describes alternative strategies in managing this patient population.


- This review article discusses the role of mTOR inhibitors in patients with advanced HCC. The mechanism of the anti-proliferative effect that mTOR inhibitors possess to have positive outcomes in patients with HCC is explained


- This primary article evaluates the use of chemoembolization (TACE) vs. radioembolization (Y90) for the management of HCC. The objective of this study was to see if the effects of TACE vs. Y90 were better or worse in downstaging HCC to allow patients to be listed for liver transplantation. 43 patients were treated with TACE and 43 patients were treated with Y90 procedures. Median tumor size at baseline was similar (5.7cm vs. 5.6cm) in TACE vs. Y90 groups. Event-free survival was significantly better in the Y90 group (17.7 vs. 7.1 months; p=0.0017). Overall survival was also significantly better in the Y90 group (41.6 vs. 19.2 months, p=0.008). The authors concluded that Y90 seemed to provide better downstaging response rates than TACE.


- This primary article discusses the use of chemoembolization in patients with HCC on the waiting list for liver transplantation. The aim of this study was to assess the dropout rate of patients who
were removed from the waiting list due to resolution of disease from chemoembolization. The dropout rate at 6 months was 15% (8 patients dropped out of the waiting list out of 54 total). This study reflects alternative options to the management of HCC aside from liver transplant, due to the rising incidence of disease and lack of transplantable organs.

3.5.4 Metabolic Diseases


- A total of 108 liver transplant recipients were enrolled. On evaluation of 88 prospective living donors, fatty liver was observed in 21 patients. After LT, 28 of 105 recipients (26.7%) developed FLD. FLD was more common in patients with a high body mass index (BMI) and dyslipidemia (both p < 0.01), primary nonalcoholic steatohepatitis (p = 0.02), after living-donor LT (p = 0.03) and everolimus (EVL) use (p = 0.08). Factors predictive of FLD included EVL use and a high BMI (hazard ratios = 3.00 and 1.34; p = 0.05 and p < 0.01, respectively). Development of FLD did not have a negative impact on LT outcome; the 5-year survival rate was 92.6%.


- Analysis of a multidisciplinary strategy to manage cardiovascular risk factors (CVRF) 12 months after LT in the post-intervention cohort (n=150) compared to a control cohort (n=100). At 12 months, significantly more patients in the post-intervention cohort had measured blood pressure, HbA1c and HDL/LDL-cholesterol. Blood pressure and HbA1c were within target in more patients with HTN and diabetes, respectively in the post-intervention cohort. Median total cholesterol levels were lower in the post-intervention cohort. At 2 years, the incidence of cardiovascular events was 14% in the control and 6% in the post-intervention cohort (p=0.063).


- Systematic review of the outcomes of liver transplantation as a treatment for Wilson's disease with neurological symptoms. Of 302 patients, 71.2% had major improvement.


- Systematic review of 9 studies analyzing the diagnostic accuracy for Wilson’s disease of biochemical tests. Study reports sensitivity and specificity of hepatic copper, 24-hour urinary copper, and ceruloplasmin using the Leipzig criteria.


- Review article that describes the risk factors associated with recurrent and de novo NAFLD, natural course of the disease, and management strategies after liver transplantation.
• Summarizes updated guideline and guidance recommendations for the management of adult NAFLD.

• Review article that discusses clinical presentation, pathophysiology, diagnosis, prognosis and management, and liver transplant and outcomes of alpha-1 antitrypsin deficiency liver disease

• Longitudinal cohort study of 602 liver transplant recipients assessing the effect of blood pressure control on cardiovascular events and mortality. Achieving blood pressure control (<140/<90 mmHg) was associated with a reduction in cardiovascular events and improved survival.

• This review discusses pre- and post-transplant management considerations for patients with end stage liver disease due to NASH.

• This review discusses the epidemiology, diagnosis and management of NASH.

• This review discusses current evidence on PTDM in patients receiving kidney, heart, liver and lung transplants.

• This review article discussed the novel therapeutic agents and current status of ongoing clinical trials with agents for the treatment of non-alcoholic fatty liver disease and/or alcoholic hepatitis.

• Review of the liver disease caused by alpha-1 antitrypsin deficiency. This review includes a discussion on pathogenesis, epidemiology, diagnostic testing, and recent therapeutic developments.

• This review article discusses the details of diagnosis, treatment, stratification, and survival data in patients with Wilson’s disease and hemochromatosis.

- This review article discusses the details of treatment of NAFLD and recurrence after transplantation. The incidence of transplantation rates as well as long-term outcomes after transplant is discussed.


- This review article discusses the details of diagnosis, pathophysiology, and clinical management of alpha-1-antitrypsin deficiency and its effect on the liver.


- The primary outcome of the trial is the number of patients who decreased ALT activity by ≥0, 3 of upper limit of normal. Results are not published yet, but the discussion of the rationale for omega-3-fatty acids is discussed. Other primary articles are referenced as well.


- The description of diagnosis and etiologies are presented in this review article. Genetic variations of disease are also discussed as well as some treatment options.


- This review articles discusses commonly raised issues relating to the current natural history, diagnosis, and management of HH patients.


- This review article discusses copper iron overload and its mechanism in causing liver injury.


- This review article discusses the details of diagnosis, treatment, stratification, and survival data in patients with Wilson's disease.

3.5.5 Cholestatic Liver Disease/Cirrhosis and Non-Cholestatic Cirrhosis


- Review of clinical implications and diagnostic issues of post-transplant immune-related cholangiopathies. Immune-mediated cholangiopathies post-transplant can be biliary lesions due to recurrence of PBC or PSC or rejection. Diagnostic workup takes into consideration indication for LT, delay since transplantation, biological abnormalities, imaging clinical context as well as biopsy of the graft.

• International, multicenter cohort analysis of liver transplant recipients to identify risk factors associated with recurrent AIH and the association between recurrent disease and patient and graft survival (n=736)
• 5-year and 10-year recurrence rate was 20% and 31%, respectively. Age at LT ≤42 years, use of MMF post-transplant, donor and recipient sex mismatch and high IgG pre-transplant were associated with higher risk of AIH recurrence.
• Recurrent AIH was significantly associated with graft loss and death.


• Prospective, multicenter, randomized, double-blind, placebo-controlled phase II proof-of-concept trial of 37 patients with PBC who were either resistant or intolerant to ursodeoxycholic acid were randomized to saroglitazar 4 mg (n=13), 2 mg (n=14), or placebo (n=10) for 16 weeks. Saroglitazar was associated with rapid and sustained improvements in alkaline phosphatase level at both 2 mg and 4 mg daily dosing. Further studies evaluating a daily dose of 2 mg and 1 mg are underway due to higher incidence of elevated liver enzymes observed with 4 mg dose.


• Systematic review and meta-analysis of 21 studies (6 RTCs and 15 observational studies) analyzing the efficacy and safety of immunomodulators in patients with PSC. In subgroup analysis, immunosuppressants (MMF, methotrexate, and tacrolimus) appeared to be most effective with the significant reduction in ALP and AST levels, but had the highest incidence of severe AEs (24.9%). Glucocorticoids (budesonide, prednisolone) moderately reduced ALP level with the lowest incidence of severe AEs (6.1%). Immunomodulators were associated with improvement in ALP, especially in patients with elevated ALP and AST levels at baseline.


• Review article on PSC pathogenesis and an algorithmic approach to diagnostic procedures and recommendations for the management of PSC and its complications, as well as promising treatment options subject to current clinical trials.


• Review article that discusses the general natural history of PBC and PSC, and provides information on the latest drug therapies currently available and those that are under investigation.


• Multicenter, international cohort study assessing incidence and risk of PBC recurrence after liver transplantation. PBC recurred in 22% at 5 years and 36% at 10 years post-transplant. Risk factors for recurrence included age <50 years at time of diagnosis, age <60 years at time of
transplant, tacrolimus use, and elevated bilirubin or alkaline phosphatase at 6 months post-transplant.


- Review article that discusses disease recurrence post-transplant and outcomes associated with disease recurrence.


- Multi-center retrospective cohort study evaluating preventative administration of ursodeoxycholic acid (UDCA) on PBC recurrence post-transplant in 90 liver transplant recipients. Preventative UDCA was associated with reduced risk of PBC recurrence after transplant.


- The current article reviews various complications associated with end-stage liver disease and treatments for managing complications.


- The current article describes risk factors, pathophysiology, and drugs more commonly associated with drug-induced cholestasis occurrence.


- The current article reviews the pathophysiology of cholestasis at the molecular level and provides a brief description of treatment options for managing cholestasis.


- Review article that discusses PBC, outcomes after transplant and PBC recurrence post-transplant.


- The current article reviews the pathophysiology of the development of cholestasis and treatment options for managing cholestasis.